E. Ohman J or Asset Management AB Has $5.32 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

E. Ohman J or Asset Management AB increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 57,590 shares of the biopharmaceutical company’s stock after acquiring an additional 7,090 shares during the period. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $5,320,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Longboard Asset Management LP bought a new position in shares of Gilead Sciences in the 4th quarter worth $204,000. Verity Asset Management Inc. grew its position in shares of Gilead Sciences by 9.2% during the 4th quarter. Verity Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 997 shares during the period. Columbus Macro LLC boosted its stake in Gilead Sciences by 55.9% during the 4th quarter. Columbus Macro LLC now owns 25,103 shares of the biopharmaceutical company’s stock worth $2,319,000 after acquiring an additional 9,004 shares during the last quarter. Finally, Trust Point Inc. grew its holdings in Gilead Sciences by 4.2% during the fourth quarter. Trust Point Inc. now owns 4,213 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 169 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a research note on Monday. Finally, Barclays increased their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In related news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 598,414 shares of company stock valued at $55,953,200 over the last ninety days. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 1.2 %

Shares of GILD stock opened at $98.38 on Tuesday. The firm’s 50-day moving average is $92.42 and its 200-day moving average is $85.96. The stock has a market cap of $122.61 billion, a price-to-earnings ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $99.45.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the firm earned $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.